31 results about "Chondrogenesis" patented technology

Biomaterials disclosed herein can comprise a hydrogel comprising PEG, gelatin, and a glycosaminoglycan with sulfated moiety; and chondrogenic, osteogenic, and immunomodulatory cytokines; wherein the biomaterial is capable of potentiating bone regeneration in a compromised wound while reducing inflammatory response. The glycosaminoglycan with sulfated moiety can comprise heparin, heparan sulfate, keratin sulfate, chondroitin sulfate, dermatan sulfate, and / or similar materials. The biomaterial can further comprise mesenchymal stem cells (MSCs), a crosslinking initiator, microparticles and nanoparticles, and or other materials. The biomaterial can be injectable into a wound, or the biomaterial can be loaded in, or further comprise a porous scaffold providing mechanical support for other components of the biomaterial, such that it can be implanted into a wound.

Disclosed are devices and methods for improving healing of an enthesis. An effective amount of a composition comprising one or more sex steroids and / or sex steroid equivalents is locally administered at the site of a repaired enthesis. The composition causes upregulation of one or more chondrogenic, angiogenic, and / or tendon modulation genes, resulting in improved healing of the enthesis. The improved enthesis healing occurs even where the subject has normal levels of sex hormones.

A method of increasing the chondrogenic potential mediated by TGFβ of a mesenchymal stromal cell (MSC) or a population of mesenchymal stromal cells (MSCs), comprising the step of increasing the amount of TGFβR1, and / or decreasing the amount of TGFβR2, and / or decreasing the amount of and / or ACVRL1 of the MSC or a population of mesenchymal stromal cells (MSCs).

The present disclosure relates to mesenchymal stem cells (MSCs) for use in a method of treatment of arthritis. The MSCs are transfected with an mRNA construct encoding a pro-chondrogenic and / or chondrocyte protective factor. The pro-chondrogenic and / or chondrocyte protective factor can be WNT3a.

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof;or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds; and methods of using such compounds for treating joint damage or injury in a mammal, for inducing hyaline cartilage production or for inducing differentiation of chondrogenic progenitor cells into mature chondrocytes.

The invention belongs to the technical field of medicines, and particularly relates to forsythiaside glucosamine, a preparation method thereof and application of the forsythiaside glucosamine in treatment of osteoarthritis. The invention relates to design and synthesis of forsythiaside glucosamine, and researches on the treatment effect of forsythiaside glucosamine on an osteoarthritis mouse model. In the structural general formula of the compound, R1 is an amino group, a phthaloyl amino group or an allyloxy amido group, R2, R3 and R4 groups represent a hydroxyl group or an alkanoyloxy group, and the configurations of different head positions are alpha and beta. Wherein the alkanoyloxy group is a C1-C6 alkanoyloxy group or a deuterated alkanoyloxy group. The synthesized forsythiaside glucosamine is used as a twin drug, and shows better cartilage generation promoting activity and anti-inflammatory activity compared with combined use of forsythiaside and glucosamine on an osteoarthritis mouse model. In addition, under the same administration dosage, the activity of promoting cartilage generation and the like is obviously superior to that of forsythiaside acetylglucosamine in the prior art.

The present invention relates to methods of producing chondrocytes, improving the phenotype of a chondrocyte population, promoting chondrogenesis, maintaining a cell population in a differentiated state or increasing the number of cells of a population in a differentiated state, producing a population of differentiated cells, and treating certain diseases or disorders. Each of these methods involves treating a cell population with, and / or culturing a cell population in, a ceramidase.

The invention relates to the technical field of nano biomedicine, and discloses an ultramicro-diameter cerium dioxide nano-enzyme, engineered dental pulp mesenchymal stem cells of the ultramicro-diameter cerium dioxide nano-enzyme and a method for improving the stability of exosomes. The ultramicro-diameter cerium dioxide nano-enzyme is prepared from citric acid and cerium nitrate hexahydrate according to the mass ratio of 2: (1.17-3.34), the preparation method comprises the following steps: mixing citric acid and cerium nitrate hexahydrate according to a mass ratio, carrying out intermittent ultrasonic treatment after mixing, and centrifuging. The diameter of the prepared citric acid and cerium nitrate hexahydrate is 1-5nm. The prepared ultramicro-diameter cerium dioxide nano-enzyme and dental pulp mesenchymal stem cells are incubated together to construct the engineered dental pulp mesenchymal stem cells, and the constructed E-DPSC can effectively maintain the redox balance in the cells, protect the cells from oxidative damage, enhance the osteogenesis and chondrogenesis differentiation capacities of the cells and improve the osteogenesis and chondrogenesis differentiation capacities of the cells. And the room-temperature physical stability of the exosome secreted by the constructed engineered dental pulp mesenchymal stem cells is effectively improved.

The invention relates to an application of citric acid in promoting chondrogenesis induced differentiation of adipose-derived stem cells, a culture solution for promoting chondrogenesis induced differentiation of adipose-derived stem cells and a method for promoting chondrogenesis induced differentiation of adipose-derived stem cells, and the method comprises the following steps: culturing adipose-derived stem cells in a culture medium for promoting chondrogenesis induced differentiation of adipose-derived stem cells, bone differentiation cells are obtained, and the bone differentiation cells are chondroblasts; the culture medium takes a chondrogenesis induction culture medium as a basic culture medium, the culture medium further comprises citric acid, and the concentration of the citric acid is 0.5-2mM. The culture solution containing citric acid is used for culturing the adipose-derived stem cells, so that the cells can obtain sufficient nutrition, cell proliferation and differentiation are facilitated, the biocompatibility is good, degradation is achieved, the cell survival time is prolonged, the cell morphology is maintained, the proliferation capacity of the adipose-derived stem cells is improved, the expression quantity of specific genes of cartilage cells is up-regulated, and the differentiation efficiency is improved.

Provided herein are methods for assaying the chondrogenesis-inducing activity of a therapeutic by measuring the expression and / or secretion levels of chondrogenesis biomarkers.

The invention provides a composite biological scaffold based on chondrocyte microspheres as well as a preparation method and application thereof, and relates to the technical field of biomedical materials. The composite biological scaffold based on the cartilage cell microspheres is prepared by using a process flow combining a microfluidic technology and a biological printing technology, taking the cartilage cell microspheres as a high-activity construction unit and taking light-cured hydrogel as a support carrier. In-vitro experiments show that the scaffold significantly improves cell viability, extracellular matrix deposition and chondrogenesis gene expression level, and meanwhile, the scaffold is stable in form; in-vivo research shows that the scaffold is highly similar to natural auricular cartilage in the aspects of macroscopic morphology, histological characteristics and mechanical strength. The composite biological scaffold provided by the invention not only can effectively promote the regeneration of the elastic cartilage, but also makes up the key defects of the traditional hydrogel scaffold, and provides an innovative strategy with clinical application value for auricle defect repair.

The present invention relates to a ground extracellular matrix (ECM) produced by a human stem cell line with chondrogenic activity, wherein the human stem cell line is genetically modified to overexpress Bone Morphogenetic Protein-2 (BMP-2). The invention further relates to a composition comprising said extracellular matrix, and a gel-like substrate or precursor thereof. The invention further relates to a kit comprising said composition. The invention further relates to a method of manufacturing said composition. The invention further relates to a method for bone and / or bone marrow formation in vivo. The invention further relates to a method for testing a candidate pharmaceutical product. The invention further relates to a method for identifying treatment responders. The invention further relates to said composition for use in medicine.

The present invention discloses a class of small molecule compounds represented by structural formulas (I)-(VII) or pharmaceutically acceptable salts, polymorphs, prodrugs, esters, metabolites, N-oxides, stereoisomers or isomers, as well as pharmaceutical compositions containing such compounds, and their use in drugs for improving osteoarthritis or related diseases of articular cartilage injury by inducing the chondrogenic differentiation of endogenous mesenchymal stem cells, and their use in drugs for promoting the in vivo cartilage repair effect of stem cells by inducing the chondrogenic differentiation of mesenchymal stem cells in vitro to improve osteoarthritis or articular cartilage defects.

This invention discloses a three-layered functional hydrogel material for osteochondral repair that promotes chondrogenesis through traditional Chinese medicine and physical stimulation, and its preparation method. Specifically, the method includes: 1) preparing a PCL electrospun membrane using electrospinning technology, and forming an HA coating on its surface using a hydrothermal method with biomimetic mineralization; 2) constructing the HA coating on the surface of black phosphorus sheets and preparing cryptotanshinone nanopowder using in-situ mineralization and spraying methods, and mixing it with BMSCs in a porous GelMA solution; 3) preparing MCSN nanoparticles loaded with baicalein using a hydrothermal template method and ultrasonic impregnation process; 4) dispersing barium titanate nanowires, drug-loaded MCSN, and BMSCs in a SilMA / HAMA solution; 5) pouring the GelMA mixture into a mold and pre-curing it, placing a plasma-treated mineralized electrospun membrane on top, then pouring the SilMA / HAMA mixture and completely curing it to obtain the desired hydrogel. This composite material has a three-layer structure, matching the needs of osteochondral repair.

The present invention provides a use of a ugonin compound for the treatment of joint-related diseases by enhancing chondrogenesis. More specifically, the chondrogenesis is mediated by the ugonin compound’s ability to promote the increase of aggrecan and type II collagen, which is achieved through the inhibition of miR-3074-5p and the activation of the MAPK signaling pathway.

The present disclosure relates to mesenchymal stem cells (MSCs) for use in a method of treatment of arthritis. The MSCs are transfected with an mRNA construct encoding a pro-chondrogenic and / or chondrocyte protective factor. The pro-chondrogenic and / or chondrocyte protective factor can be WNT3a.

Improved compositions and methods for generating chondrocytes and cartilage tissues from human pluripotent stem cells are provided. Methods include use of one or more of FGF agonist, cAMP agonist, and TGFβ agonist to induce chondrogenesis in monolayer culture. Articular cartilage tissues generated using the methods have zonal organization similar to native cartilage tissue including surface chondrocytes and intermediate zone chondrocytes, with increased extracellular matrix components consistent with native cartilage tissue. These biochemical and mechanical properties make the cartilage tissue particularly suited for tissue implants in vivo.

The present invention relates to 8-aryl-substituted and 8-heteroaryl-substituted 9H-pyrido[3,4-b]indoles of the formula (I), in which A, E, G, R1 to R6 and R10 are as defined in the claims, which stimulate chondrogenesis and cartilage matrix synthesis and can be used in the treatment of cartilage disorders and conditions in which a regeneration of damaged cartilage is desired, for example joint diseases such as osteoarthritis. The invention furthermore relates to processes for the synthesis of the compounds of the formula (I), their use as pharmaceuticals, and pharmaceutical compositions comprising them.

Provided herein are systems of modulating gene expression, methods of use thereof, and cells engineered thereof for the purpose of differentiating cells, for example chondroprogenitor cells.

The present disclosure relates to mesenchymal stem cells (MSCs) for use in a method of treatment of arthritis. The MSCs are transfected with an mRNA construct encoding a pro-chondrogenic and / or chondrocyte protective factor. The pro-chondrogenic and / or chondrocyte protective factor can be TGFβ3.

Chondrogenic potential of mesenchymal stem cells (MSCs) can be determined using magnetic resonance relaxometry by measuring T2 relaxation value of the MSCs.

Compositions comprising at least one retinoid acid receptor agonist are disclosed. Methods for inhibiting, treating, and / or preventing a chondrogenesis-related disease or disorder in a subject, comprising administering to a subject at least one retinoid acid receptor (RAR) agonist are further disclosed.

The invention discloses a meniscus organ construction method based on voxelization variable wire diameter printing and an obtained product. The method comprises the following steps: acquiring target meniscus medical image data and establishing a voxelization model; printing parameters are mapped according to mechanical distribution; the PCL stent is constructed by adopting a variable-wire-diameter melt extrusion technology, fibers are laid in a 0-degree / 60-degree / 120-degree three-axis staggered manner, the wire diameter is continuously adjustable in a range of 150-350 microns, and the porosity is from 80% to 10% in an inner region to 10% in an outer region; tGF-beta functional NorCol ink is injected into the inner area through a multi-nozzle system, and CTGF functional NorCol ink is injected into the outer area; packaging the hUC-MSCs at the density of 2 * 10 < 6 > cells / mL, performing cartilage differentiation culture for 28 days after 405nm light in-situ crosslinking, and applying periodic mechanical loading during the period. The invention also relates to the prepared meniscus organ and application of the meniscus organ in preparation of a graft. According to the scheme, continuous mechanical gradient reconstruction and regional biochemical microenvironment construction are realized, and the problems of insufficient mechanical bionics and limited regional induction in the prior art are solved.

The present invention discloses an application of Avenanthramide C (Avn C) as an inducer of chondrocyte differentiation in Mesenchymal Stem Cells (MSCs), providing a promising approach for regenerative cartilage therapies. By employing Avn C treatments, MSCs exhibit enhanced chondrocyte differentiation with elevated expression of key specific chondrogenic extracellular matrix (ECM) factors, notably collagen type 2 (COL2A1). Moreover, a synergistic effect is observed when Avn C is used in combination with Chondroitin Sulfate (CS), resulting in the upregulation of the transcriptionally active state of SOX9, a crucial regulator of chondrogenesis. The disclosed invention demonstrates significant improvements in mRNA gene expressions (ACAN, LRP1, SOX9), cellular protein levels (COL2A1, SOX9, LRP1), and functional outcomes, as evidenced by the secretion of extracellular matrix proteins (FSTL-1, BGH3, CO1A1, CO1A2, and CO3A1).

The present invention relates to a chondrogenesis-stimulating spheroid and, more specifically, to a pharmaceutical composition for preventing or treating osteoarthritis, comprising, as an active ingredient, spheroid-type chondrocytes to which a chondrogenesis stimulus has been applied, and a method for producing a chondrogenesis-stimulating spheroid.

The present invention relates to 8-aryl-substituted and 8-heteroaryl-substituted 9H-pyrido[3,4-b]indoles of the formula (1), in which A, E, G, R1 to R6 and R10 are as defined in the claims, which stimulate chondrogenesis and cartilage matrix synthesis and can be used in the treatment of cartilage disorders and conditions in which a regeneration of damaged cartilage is desired, for example joint diseases such as osteoarthritis. The invention furthermore relates to processes for the synthesis of the compounds of the formula (I), their use as pharmaceuticals, and pharmaceutical compositions comprising them.

The present application relates to the technical field of hydrogel and its preparation, and discloses a chitosan-based gradient hydrogel, a preparation method and application thereof, wherein thiolated chitosan and curcumin-loaded multivesicular liposomes are dissolved in an alpha-ketoglutaric acid aqueous solution, N-hydroxysuccinimidyl acrylate and hydroxyapatite are dissolved in another deionized water, and the two solutions are mixed, and the pH value of the system is adjusted to neutral to obtain a bone layer gel. According to the above gel preparation method, the hydroxyapatite is replaced by cartilage root to obtain a cartilage layer gel. The bone layer gel is placed at the bottom layer, and the cartilage layer gel is placed at the top layer, and a chitosan-based gradient hydrogel is prepared integrally. The chitosan-based bone-cartilage gradient hydrogel constructed by the present application can better simulate the bone-cartilage gradient structure and the bone-cartilage interface, the cartilage layer gel promotes chondrogenesis, the bone layer gel promotes osteogenesis, and the slow release of curcumin adjusts the inflammatory microenvironment to maintain the phenotype.

The invention discloses application of circCRIM1 in regulation and control of cartilage cell differentiation and cartilage homeostasis, and relates to the technical field of gene engineering. The invention discloses an application of circCRIM1 in regulation and control of cartilage cell differentiation and cartilage homeostasis. A nucleotide sequence of the circCRIM1 is shown as SEQ. ID. NO.1; experiments prove that circCRIM1 is highly expressed in osteoarthritis cartilage, and the inhibition effect of circCRIM1 on MMP16 is relieved through specific binding of circCRIM1 to miR-320c, so that cartilage generation of human adipose-derived stem cells is inhibited, cartilage cell homeostasis is destroyed, and cartilage matrix degradation is promoted. Based on the mechanism, the invention can provide a new target and strategy for clinically and effectively delaying the progress of osteoarthritis and treating osteoarthritis.

The present disclosure relates to mesenchymal stem cells (MSCs) for use in a method of treatment of arthritis. The MSCs are transfected with an mRNA construct encoding a pro-chondrogenic and / or chondrocyte protective factor. The pro-chondrogenic and / or chondrocyte protective factor can be TGFβ3.